Featured Research

from universities, journals, and other organizations

Higher mortality in postmenopausal women with RA and anti-CCP antibodies

Date:
December 23, 2013
Source:
Wiley
Summary:
New research shows mortality rates are two times higher in postmenopausal women with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Findings indicate the higher mortality rates persisted after adjusting for age, positive rheumatoid factor, positive antinuclear antibodies (ANA) and disease modifying anti-rheumatic drug (DMARD) use.

New research shows mortality rates are two times higher in postmenopausal women with rheumatoid arthritis (RA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Findings published in the American College of Rheumatology (ACR) journal Arthritis & Rheumatism, soon to be called Arthritis & Rheumatology, indicate the higher mortality rates persisted after adjusting for age, positive rheumatoid factor, positive antinuclear antibodies (ANA) and disease modifying anti-rheumatic drug (DMARD) use.

According to the ACR, RA affects 1.3 million adults in the U.S. with 75% of those being women. Previous studies report that RA patients have mortality rates 1.5-fold higher than healthy controls. Medical evidence suggests that excess mortality is mainly caused by cardiovascular disease and is greater in groups with existing RA compared to those newly diagnosed. However, observational data indicate that methotrexate may reduce cardiovascular disease and mortality.

For the present study researchers from the University of Pittsburgh, led by Drs. Lewis Kuller and Larry Moreland, measured anti-CCP, rheumatoid factor and ANA in close to 10,000 women who self-reported RA as part of the Women's Health Initiative (WHI) -- clinical trials and observational study of postmenopausal women, conducted by the National Institutes of Health (NIH). Participants included in the present research had a mean age of 64 years with 65% white, 25% black and 10% Hispanic.

Results show that anti-CCP was prevalent in 8.1% of the group, of whom 58% reported DMARD use during follow-up. Only 7.3% of the remaining 9,179 women with self-report RA, but negative anti-CCP, were using DMARDs. During the 10-year study period, 13% of women died -- 14% who self-reported RA at the start of the study and follow-up; 16% who reported RA at baseline; and 11% who reported RA at follow-up.

Further analysis determined that cardiovascular disease, including coronary heart disease and stroke, and cancer were the main cause of death among women with RA. Women with positive anti-CCP had a substantially higher mortality risk that was independent of DMARD use, including methotrexate, and modifiable risk factors (obesity, smoking) associated with mortality.

"Our study is the first large longitudinal study to evaluate anti-CCP, RF, risk factors and mortality," said Dr. Kuller. "Further investigation to determine specific causes of excess mortality, particularly among RA patients with positive anti-CCP, are needed."


Story Source:

The above story is based on materials provided by Wiley. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lewis H. Kuller, Rachel H. Mackey, Brian T. Walitt, Kevin D. Deane, V. Michael Holers, William H. Robinson, Jeremy Sokolove, Yuefang Chang, Simin Liu, Christine G. Parks, Nicole C. Wright, Larry W. Moreland. Determinants of mortality among postmenopausal women who report rheumatoid arthritis in the Women's Health Initiative. Arthritis & Rheumatism, 2013; DOI: 10.1002/art.38268

Cite This Page:

Wiley. "Higher mortality in postmenopausal women with RA and anti-CCP antibodies." ScienceDaily. ScienceDaily, 23 December 2013. <www.sciencedaily.com/releases/2013/12/131223083809.htm>.
Wiley. (2013, December 23). Higher mortality in postmenopausal women with RA and anti-CCP antibodies. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2013/12/131223083809.htm
Wiley. "Higher mortality in postmenopausal women with RA and anti-CCP antibodies." ScienceDaily. www.sciencedaily.com/releases/2013/12/131223083809.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins